Skip to content

Stress-induced Scratching in Healthy and AD

The Cerebral Mechanism of Stress-Induced Spontaneous Scratching in Healthy Volunteers and Patients With Atopic Dermatitis (AD)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04174651
Enrollment
8
Registered
2019-11-22
Start date
2020-01-27
Completion date
2022-07-19
Last updated
2022-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis, Healthy

Brief summary

The purpose of this study is to examine scratching behavior and identify brain areas responsible for stress-induced spontaneous scratching in patients with atopic dermatitis (AD).

Interventions

Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.

BEHAVIORALLandscape Video

Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.

Sponsors

University of Miami
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Crossover randomization within the arms.

Eligibility

Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy subjects and AD patients between 18 and 59 years of age. 2. Healthy subjects: In general, good health without history of neurological and psychiatric diseases. 3. AD patients: An average itch rating of 3 out of 10 or greater in the past two weeks using a Numerical Rating Scale (NRS). 4. All patients will be required to cease use of oral antihistamines from the night before each study visit until the end of the experiment. The purpose is to avoid that participants fall asleep during MRI measurement due to side effect oral antihistamine (i.e., sedation). 5. Women of child bearing potential will be administered a pregnancy test to verify that they are not pregnant. 6. MRI Compatibility, criteria include having no major contraindication for MRI (pacemaker, vascular stents, metallic ear tubes, and absence of metal implants or braces) as assessed by MRI technologist using site approved screening form. 7. Participants have to be able to speak and read English fluently. 8. Participants must have signed a written informed consent before being enrolled in the study

Exclusion criteria

1. Individuals under 18 or over 59 years of age. 2. Inability to complete the required measures. 3. Suffering from any disease state or physical condition, which would increase their health risk by study participation. 4. Currently enrolled in any investigational study in which the subject is receiving any type of drug, biological, or non-drug therapy. 5. Recent initiation (within last 3 months) of centrally acting agents such as antidepressants, neuroleptics or neuropathic medications. 6. Patients who use centrally acting agents only when they need. The purpose is to avoid a risk of acute effect of these agents on brain activity and perceived stress due to the stress task. 7. Current treatment with opioid analgesics. 8. Uncontrolled thyroid disease. 9. Use of illicit drugs or history of opiate addiction. 10. Diagnosis of a major psychiatric disorder such as schizophrenia, major depression or bipolar disorder that is active right now. 11. Any known diseases or disorders that may affect conducting the experiments (e.g., intracranial pathology, claustrophobia, severe respiratory or cardiovascular problems, active fibromyalgia) or diseases that have potential risks of infections (e.g., HIV, Hepatitis C, etc). 12. Inability to speak and read English. 13. Being pregnant. 14. Incarcerated.

Design outcomes

Primary

MeasureTime frameDescription
Changes in brain activityBaseline, 15 minutesChanges in brain activity will be measured as change in Arterial spin Labeling (ASL) which reflects regional cerebral blood flow. This will be evaluated using functioning magnetic resonance imaging (fMRI).
Change in time of spontaneous scratchingBaseline, 15 minutesChange in spontaneous scratching for behavioral only arms will be calculated by subtracting total duration of scratching behavior before and after the TSST and Landscape video.

Secondary

MeasureTime frameDescription
Correlation of perceived stress with stress-induced brain activity60 minutesThe correlation of stress-induced brain activity evaluated as ASL signals will be evaluated against participant's stress questionnaire scores and biological stress marker (saliva cortisol levels).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026